Interactions of Mitomycin C with Mammalian DMA Detected by Alkaline Elution1

Total Page:16

File Type:pdf, Size:1020Kb

Interactions of Mitomycin C with Mammalian DMA Detected by Alkaline Elution1 [CANCER RESEARCH 45, 3510-3516, August 1985] Interactions of Mitomycin C with Mammalian DMA Detected by Alkaline Elution1 Robert T. Dorr,2 G. Timothy Bowden, David S. Alberts, and James D. Liddil Departments ol Medicine [fí.T. D., D. S. A., J. D. L] and Radiology [G. T. B.J, Cancer Center Division, The University of Arizona, Tucson, Arizona 85724 ABSTRACT and by DNA renaturation studies using enhanced ethidium dye intercalation to indicate cross-linking (7). These studies used The antitumor antibiotic mitomycin C (MMC) was studied in bacterial or X-phage DNA and could not evaluate the dynamics vitro using L1210 leukemia and 8226 human myeloma cells. or specific type of DNA cross-linking produced by MMC due to Cytotoxicity was evaluated by colony formation in soft agar, and assay limitations. An alternate technique, DNA alkaline elution, DMA damage was analyzed using alkaline elution filter assays. has been useful in quantitating both the time course and dose- The purposes of these studies were: (a) to characterize the time response relationships of mammalian DNA cross-linking for a course of MMC-DNA damage; (b) to characterize the type of large number of alkylating agents. These include the bischloro- DNA damage [DNA-DNA interstrand cross-links (ISC), DNA- ethylamines, mechlorethamine (nitrogen mustard or HN2), and protein cross-links (DPC), single and double strand breaks melphalan (10), the platinum coordination compound cisplatin (SSBs, DSBs)]; and (c) to correlate this damage with cytotoxicity (11) and the chloroethylnitrosoureas (12). In addition to time and in vitro. Colony-forming assays showed the D0 value for 1 h dose studies, the alkaline elution technique can be modified to MMC to be 15.0 UM for L1210 cells and 17 nu for 8226 cells. differentiate DNA-DNA ISC, DPCs, and DNA SSBs produced by Alkaline elution studies showed that dose-dependent ISCs and a given drug treatment (13). In this report, we describe the rapid DPCs formed rapidly following MMC exposure. Removal of formation and slow elimination of DNA-DNA ISCs and DPCs cross-links was delayed, with only 50% repaired 32 h after produced by MMC in mammalian L1210 cell DNA as analyzed exposure. There was a good correlation between ISCs and by the alkaline elution technique. A brief preliminary description cytotoxicity in dose-response studies in each cell line. ISCs of these investigations has been reported previously (14). appeared to comprise most of the MMC-DNA lesions in both cell lines. No DNA SSBs or DSBs were observed following MMC MATERIALS AND METHODS exposure. Nuclei isolated from both cell lines and exposed to MMC produced less MMC alkylation than whole cells but, again, Cell Cultures. Murine L1210 leukemia cells were maintained and no strand breaks were evident. These results demonstrate that treated in suspension in RPMl 1640 medium supplemented with 10% MMC is principally an alkylating agent when used at pharmaco (vol/vol) fetal calf serum, 1% (v/v) penicillin (100 units/ml), and strepto logical (cytotoxic) concentrations In vitro. The lack of evidence mycin (100 ^g/ml) (all from Grand Island Biological Co.). The cells were for DNA strand breaks discounts a significant role for putative grown in 10% COz-90% air atmosphere at 37°C. Cells in logarithmic quinone-generated oxygen free radicals in the production of growth (doubling time of 12 h) were labeled in complete medium for 36 h by the addition of [2-14C]thymidine [0.1 /iCi/ml; 55 mCi/mmol (Research MMC cytotoxicity. Products International Corp., Mount Prospect, IL)]. Cells were "chased" in nonradioactive medium for an additional 12 h prior to drug treatments. INTRODUCTION Cells suspended in complete medium were exposed to MMC (Mutamy- cin; Bristol Laboratories, Syracuse, NY) diluted in phosphate-buffered MMC3 is a Sfreptomyces-derived antibiotic with anticancer saline (0.15 M NaCI, 0.71 mw KH2PO4, and 4.28 mw K2HPO4, pH 7.4) and maintained for 1 h at 37°C. After 1 h, drug was removed by activity in a variety of human tumors (1, 2). Early observations by Iyer and Szybalski (3, 4) documented the cross-linking of centrifugation twice at 800 x g into iced fresh complete medium. Iced cell suspensions (3 to 1 x 10^/ml) were irradiated with X-rays at 3 Gy/ complementary DNA strands as the molecular mechanism of its min using a 4-MeV linear accelerator (Linac 4; VaríanAssociates, Palo cytotoxic action. Besides DNA alkylation, recent reports have Alto, CA). The human myeloma cell line RPMl 8226 (CCL155; American also suggested that MMC can produce DNA strand scission via Type Culture Collection, Rockville, MD) was treated similarly but with a quinone-generated oxygen free radicals (5-7). The contribution modification to increase the [14C]thymidine labeling time to 60 h to of oxygen free radical effects to MMC cytotoxicity is not estab accommodate the slower tumor doubling time of approximately 32 h. lished. Indeed, DNA cross-linking appears to correlate well with Nuclear isolation was performed according to the method of Ross er MMC cytotoxicity in terms of drug doses (8) and the onset of al. (15). Phase microscopy was used to confirm the presence of nuclei effects (9). in the final preparation. The cross-linking effects of MMC have been studied using A standard double layer soft-agar plating system was used to evaluate MMC activity against exponentially growing L-1210 and 8226 cells in DNA thermal denaturation and buoyant density techniques (3) vitro (16). MMC (Mutamycin) was added to cell suspensions for 1 h at 1 Supported in part by Grants CA 23074, CA 17094, CA 26972, and CA 17343 37°C. from the National Cancer Institute, NIH, Department of Health and Human Services, Following drug exposure, cells were washed twice by centrifugation Bethesda, MD 20205. (800 x g) and plated at 4 x 104 cells/ml (L1210) or 2 x 10s cells/ml Presented in part at the Seventy-fifth Annual Meeting of the American Associa (8226) into 35-mm Petri dishes containing 0.3% agar in complete me tion for Cancer Research, May 10,1984, Toronto, Canada (14). 2To whom requests for reprints should be addressed, at Cancer Center, Arizona dium. Triplicate plates were incubated under 10% CO2 and 90% hu Health Sciences Center, 1501 N. Campbell Avenue, Tucson, A2 85724. midified air to facilitate colony formation. Colonies of >60 pm size were 'The abbreviations used are: MMC, mitomycin C; ISC, ¡nterstrand DNA-DNA cross-links; DPC, DNA-protein cross-links; SSB, single-strand breaks; DSB, double- counted 5 to 7 days after plating (L1210) or 10 to 14 days after plating (8226) by an automated image analysis system |FAS-ll Omincon; Bausch strand breaks; SDS, sodium dodecyl sulfate. Received 12/14/84; revised 4/24/85; accepted 4/26/85. and Lomb, Rochester, NY (17)]. CANCER RESEARCH VOL. 45 AUGUST 1985 3510 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1985 American Association for Cancer Research. MMC CYTOTOXICITY AND DNA CROSS-LINKING Alkaline DNA Elution. The technical and theoretical aspects of this to-one-terminus model of Ross ef al. (23): procedure have been reviewed in detail elsewhere (13). Briefly, 1.0 x 106 L1210 or 0.5 x 106 8226 cells were exposed to drug, washed by PC=KI- r)-1-(1 (C) centrifugation in cold medium, irradiated on ice, and loaded gently into 50-ml filter stacks housing a 25-mm, 2-/¿mpore size Polyvinylchloride where Po is the frequency of DNA single strand breaks produced by 30 Gy and r and r0 are the fractions of DNA eluting in the slow elution phase filter (Type BS; Millipore Corp., San Francisco, CA). The cells were washed with ice-cold phosphate-buffered saline and lysed immediately in the presence or absence of drug, respectively. The degree to which r exceeds r0 is a measure of DPCs. DNA SSB and DSBs induced by MMC on the filters with 5 ml of pH 10.0 detergent solution in the presence or were also quantitated as Gy-equivalents, defined as the dose of radiation absence of proteinase k (0.5 mg/ml). Assays performed to detect total DNA cross-linking used a lysis solution of 2 M NaCI, 0.04 M disodium which produces an equivalent number of DNA strand breaks in control EDTA, 0.2% AMauroylsarcosine, and a pH 12.1 elution solution of tetra- experiments with radiation alone (17). propylammonium hydroxide (Eastman Organic Chemicals, Rochester, NY). Assays performed to detect DNA-DNA ISC were performed with a RESULTS pH 10.0 lysis solution of proteinase k (0.5 mg/ml) (E. Merck Co., Darmstadt, Germany; Type XI fungal from Tritirachium alba 10-20-m The survival of L1210 cells following a 1-h exposure to various Anson units/mg of protein) 2% SDS, 0.1 M glycine, 0.02 M disodium doses of MMC was determined by cloning in soft agar (Chart 1). EDTA, and a pH 12.1 elution solution of 1% SDS/0.02 M EDTA/tetrapro- The quasithreshold dose (DQ) for MMC against exponentially plyammonium hydroxide. For DPC assays, the AMauroylsarcosine lysis and non-SDS-containing elution solutions were used. In this latter assay, growing L1210 cells was approximately 5.0 ¿/M/h.The mean lethal dose (D0) was approximately 15 ^M) (5 ¿<g/ml).DNAcross- cells were irradiated to a total of 30 Gy to produce very short DNA strands which are retained on the PVC filters only if the DNA strand is linking in L1210 cells exposed to MMC was assessed by 3 covalently linked to a large protein (18). To assess whether DNA SSBs alkaline elution techniques.
Recommended publications
  • Use of Anti-Vegf Antibody in Combination With
    (19) TZZ __T (11) EP 2 752 189 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/337 (2006.01) A61K 39/395 (2006.01) 26.10.2016 Bulletin 2016/43 A61P 35/04 (2006.01) A61K 31/513 (2006.01) A61K 31/675 (2006.01) A61K 31/704 (2006.01) (2006.01) (21) Application number: 13189711.8 A61K 45/06 (22) Date of filing: 20.11.2009 (54) USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER VERWENDUNG VON ANTI-VEGF ANTIKÖRPER IN KOMBINATION MIT CHEMOTHERAPIE ZUR BEHANDLUNG VON BRUSTKREBS UTILISATION D’ANTICORPS ANTI-VEGF COMBINÉS À LA CHIMIOTHÉRAPIE POUR LE TRAITEMENT DU CANCER DU SEIN (84) Designated Contracting States: (74) Representative: Denison, Christopher Marcus et al AT BE BG CH CY CZ DE DK EE ES FI FR GR HR Mewburn Ellis LLP HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT City Tower RO SE SI SK SM TR 40 Basinghall Street London EC2V 5DE (GB) (30) Priority: 22.11.2008 US 117102 P 13.05.2009 US 178009 P (56) References cited: 18.05.2009 US 179307 P US-A1- 2009 163 699 (43) Date of publication of application: • CAMERON ET AL: "Bevacizumab in the first-line 09.07.2014 Bulletin 2014/28 treatment of metastatic breast cancer", EUROPEAN JOURNAL OF CANCER. (60) Divisional application: SUPPLEMENT, PERGAMON, OXFORD, GB 16188246.9 LNKD- DOI:10.1016/S1359-6349(08)70289-1, vol. 6, no.
    [Show full text]
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • Ginsenosides Synergize with Mitomycin C in Combating Human Non-Small Cell Lung Cancer by Repressing Rad51-Mediated DNA Repair
    Acta Pharmacologica Sinica (2018) 39: 449–458 © 2018 CPS and SIMM All rights reserved 1671-4083/18 www.nature.com/aps Article Ginsenosides synergize with mitomycin C in combating human non-small cell lung cancer by repressing Rad51-mediated DNA repair Min ZHAO, Dan-dan WANG, Yuan CHE, Meng-qiu WU, Qing-ran LI, Chang SHAO, Yun WANG, Li-juan CAO, Guang-ji WANG*, Hai-ping HAO* State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China The use of ginseng extract as an adjuvant for cancer treatment has been reported in both animal models and clinical applications, but its molecular mechanisms have not been fully elucidated. Mitomycin C (MMC), an anticancer antibiotic used as a first- or second- line regimen in the treatment for non-small cell lung carcinoma (NSCLC), causes serious adverse reactions when used alone. Here, by using both in vitro and in vivo experiments, we provide evidence for an optimal therapy for NSCLC with total ginsenosides extract (TGS), which significantly enhanced the MMC-induced cytotoxicity against NSCLC A549 and PC-9 cells in vitro when used in combination with relatively low concentrations of MMC. A NSCLC xenograft mouse model was used to confirm thein vivo synergistic effects of the combination of TGS with MMC. Further investigation revealed that TGS could significantly reverse MMC-induced S-phase cell cycle arrest and inhibit Rad51-mediated DNA damage repair, which was evidenced by the inhibitory effects of TGS on the levels of phospho- MEK1/2, phospho-ERK1/2 and Rad51 protein and the translocation of Rad51 from the cytoplasm to the nucleus in response to MMC.
    [Show full text]
  • Sex-Specific Effects of Cytotoxic Chemotherapy Agents
    www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment.
    [Show full text]
  • Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
    Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI.
    [Show full text]
  • The Role of Drug Transport in Resistance to Nitrogen Mustard and Other Alkylating Agents in L5178Y Lymphoblasts1
    [CANCER RESEARCH 35.1687 1692, July 1975] The Role of Drug Transport in Resistance to Nitrogen Mustard and Other Alkylating Agents in L5178Y Lymphoblasts1 Gerald J. Goldenberg2 Department of Medicine. University of Manitoba, and the Manitoba Institute of Cell Biology. Winnipeg. Manitoba. R3E OV9, Canada SUMMARY (19, 20) in normal and leukemic human lymphoid cells (25) and in rat Walker 256 carcinosarcoma cells in vitro (18). An investigation was undertaken of the mechanism of Choline, a close structural analog of HN2, has been resistance to nitrogen mustard (HN2) and other alkylating identified as the native substrate for the HN2 transport agents, with particular emphasis on the interaction between system (19). Other alkylating agents, including chlorambu cross-resistance and drug transport mechanisms in LSI78Y cil, melphalan, and intact and enzyme-activated cyclophos lymphohlasts. Dose-survival curves demonstrated that the DOfor HN2-sensitive cells (L5178Y) treated with HN2 in phamide, did not inhibit HN2 transport, suggesting inde vitro was 9.79 ng/ml and the D0 for HN2-resistant cells pendent transport mechanisms for these agents (20). Unlike HN2 transport, a study of cyclophosphamide uptake by (L5178Y/HN2) was 181.11 ng/ml; thus, sensitive cells were 18.5-fold more responsive than were resistant cells and the LSI78Y lymphoblasts demonstrated biphasic kinetics and was mediated by a facilitated diffusion mechanism (15). In difference was highly significant (p < 0.001). A similar common with HN2 transport, uptake of cyclophosphamide evaluation of 5 additional alkylating agents, including chlorambucil, melphalan, l,3-bis(2-chloroethyl)-l-nitro- was not blocked by other alkylating agents such as HN2, sourea, Mitomycin C, and 2,3,5-tris(ethyleneimino)-l,4- chlorambucil, melphalan and isophosphamide, providing additional evidence that these drugs are transported by benzoquinone, revealed that L5178Y/HN2 cells were also cross-resistant, in part, to each of these compounds.
    [Show full text]
  • Antibiotics for Cancer Treatment
    Journal of Cancer 2020, Vol. 11 5135 Ivyspring International Publisher Journal of Cancer 2020; 11(17): 5135-5149. doi: 10.7150/jca.47470 Review Antibiotics for cancer treatment: A double-edged sword Yuan Gao1,2, Qingyao Shang1,2, Wenyu Li1,2, Wenxuan Guo1, Alexander Stojadinovic3, Ciaran Mannion3,4, Yan-gao Man3 and Tingtao Chen1 1. National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, 1299 Xuefu Road, Honggu District, Nanchang, 330031 People’s Republic of China. 2. Queen Mary School, Nanchang University, Nanchang, Jiangxi 330031, PR China. 3. Department of Pathology, Hackensack University Medical Center, 30 Prospec Avenue, Hackensack, NJ 07601, USA. 4. Department of Pathology, Hackensack Meridian School of Medicine at Seton Hall University, 340 Kingsland Street, Nutley, NJ 07110, USA. Corresponding author: Dr. Tingtao Chen Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China; E-mail: [email protected]; Tel: +86-791-83827170, or Dr. Yan-gao Man, Man Department of Pathology, Hackensack Meridian Health-Hackensack University Medical Center, NJ, USA; e-mail: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.04.27; Accepted: 2020.06.14; Published: 2020.06.28 Abstract Various antibiotics have been used in the treatment of cancers, via their anti-proliferative, pro-apoptotic and anti-epithelial-mesenchymal-transition (EMT) capabilities. However, increasingly studies have indicated that antibiotics may also induce cancer generation by disrupting intestinal microbiota, which further promotes chronic inflammation, alters normal tissue metabolism, leads to genotoxicity and weakens the immune response to bacterial malnutrition, thereby adversely impacting cancer treatment.
    [Show full text]
  • EFFORTS TOWARD the TOTAL SYNTHESIS of MITOMYCINS By
    EFFORTS TOWARD THE TOTAL SYNTHESIS OF MITOMYCINS by ANNE VIALETTES Ingénieur de l’École Supérieure de Chimie, Physique Électronique de Lyon, spécialité: Chimie - Chimie des Procédés, 2007 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Chemistry) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) May 2009 © Anne Vialettes, 2009 ABSTRACT This thesis describes our efforts toward the total synthesis of mitomycins. The centerpiece of our route to the target molecule is a homo-Brook mediated aziridine fragmentation, developed in our laboratory. The aziridine moiety of the target molecule was installed through an intramolecular iodoamidification of an olefin. The crystalline triazoline intermediate, available before the homo-Brook rearrangement, was obtained after Reetz allylation on an aldehyde followed by a intramolecular 1,3-diploar cycloaddition of an azido unit onto a terminal olefin. The aldehyde intermediate was synthesized in 9 steps involving a Mitsunobu reaction, a Claisen rearrangement and a Lemieux-Johnson oxidation from readily commercially available products. ii TABLE OF CONTENTS ABSTRACT ....................................................................................................................................ii TABLE OF CONTENTS ..................................................................................................................iii LIST OF FIGURES .........................................................................................................................
    [Show full text]
  • For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline
    ANTICANCER RESEARCH 36: 419-426 (2016) Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline KATRIN ALMSTEDT1, PETER A. FASCHING1, ANTON SCHARL2, CLAUDIA RAUH1, BRIGITTE RACK3, ALEXANDER HEIN1, CAROLIN C. HACK1, CHRISTIAN M. BAYER1, SEBASTIAN M. JUD1, MICHAEL G. SCHRAUDER1, MATTHIAS W. BECKMANN1 and MICHAEL P. LUX1 1Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany; 2Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany; 3Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany Abstract. Background/Aim: The aim of this single-arm, (MBC) is still a challenge. The majority of patients with prospective, multicenter phase II trial (MiX) was to increase breast cancer receive an anthracycline-based regimen as first treatment options for women with metastatic breast cancer chemotherapy, in an adjuvant, neoadjuvant, or metastatic pretreated with anthracycline and taxane by evaluation of the setting. The development of drug resistance and impairment efficacy and toxicity of the combination of mitomycin C and of organ functions limits the choice of further cytotoxic capecitabine. Patients and Methods: From 03/2004 to drugs in the metastatic situation. Although many patients are 06/2007, a total of 39 patients were recruited and received willing to receive further anticancer therapy to counteract mitomycin C in combination with capecitabine. The primary tumor growth, they often request a less toxic but still end-point was to determinate the tumor response according effective therapy. At present taxanes (e.g. paclitaxel, to Response Evaluation Criteria in Solid Tumors and the rate docetaxel, nab-paclitaxel), eribulin, vinorelbine, 5- of toxicities (safety).
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline >50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]
  • Possible Intermediates in the Action of Adriamycin a Pulse Radiolysis Study E.J
    Br. J. Cancer (1985), 51, 515-523 Possible intermediates in the action of adriamycin A pulse radiolysis study E.J. Land', T. Mukherjeel*, A.J. Swallow' & J.M. Bruce2 'Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX and the 2Department of Chemistry, The University, Manchester M13 9PL, UK. Summary Over a wide range of pH, the semiquinone free radicals formed by reduction of adriamycin exist as a form which is strongly stabilised by internal hydrogen bonding and resonance. They protonate with pKa = 2.9. Below this pH they exhibit absorption maxima at 430nm (smax = 13,200dm3mol-'cm-1) and -720nm (Cmax =4,200dm3mol3-1 cm -). Above pH 2.9 they have maxima at 480 nm (smax= 14,600 dM3mol-1 cm-') and - 700 nm (Smax = 3,400 dm mol -cm -'). In acid and alkaline solution the radicals rapidly disappear by disproportionation, but within the approximate pH range 6 to 11 they appear to be relatively stable for at least 10-20ms, existing in transient equilibrium with parent adriamycin and the full reduced form. Some rate constants for the formation and reactions of the semiquinone are given, including the reaction with oxygen to give 0i-. Fully reduced adriamycin has absorption maxima at 410 nm (smax = 11,000dm3 mol-lcm-') at pH 5 and 430 nm (Vmax=19,000dm3mol- cm -) at pH 11. It undergoes decomposition within a few hundred ms. The intermediates from daunomycin would be expected to have properties similar to those from adriamycin. Anthracycline antibiotics constitute a major class of or hydroxyl (OH'), which could react with the chemotherapeutic agents for the treatment of proximal DNA, producing the strand-scission different kinds of cancer.
    [Show full text]